Related Experiment Video
Updated: Jul 11, 2026
Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death
Published on: August 15, 2022
[Living-donor lobar lung transplantation for infectious lung diseases]
Hiroshi Date1, M Yamane, S Toyooka
1Department of Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine, Okayama, Japan.
Abstract:
The rate of infection among lung transplant recipients is several times higher than that among recipients of other organs and is most likely related to the exposure of the allograft to the external environment. Meticulous peri-operative management is mandatory in performing living-donor lobar lung transplantation for patients with infectious lung diseases. All 5 patients with end-stage infectious lung diseases are currently alive for 17-104 months after receiving living-donor lobar lung transplantation at Okayama University Hospital.
Insights
Lung transplant recipients face higher infection risks due to allograft exposure. Living-donor lobar lung transplantation with careful peri-operative management offers a viable option for patients with infectious lung diseases, with all 5 patients surviving long-term.
Area of Science:
- Infectious diseases
- Transplantation immunology
- Thoracic surgery
Context:
- Lung transplant recipients experience significantly higher infection rates compared to other organ transplant recipients.
- This increased susceptibility is attributed to the direct exposure of the lung allograft to the external environment.
- Patients with end-stage infectious lung diseases present unique challenges for lung transplantation.
Purpose:
- To evaluate the efficacy and safety of living-donor lobar lung transplantation (LDLLT) in patients with end-stage infectious lung diseases.
- To highlight the critical role of meticulous peri-operative management in mitigating infection risks.
- To assess the long-term survival outcomes following LDLLT in this high-risk patient cohort.
Summary:
- A study was conducted at Okayama University Hospital involving 5 patients with end-stage infectious lung diseases who underwent living-donor lobar lung transplantation.
- Rigorous peri-operative protocols were implemented to manage the inherent risks associated with lung transplantation in infectious disease patients.
- All 5 patients demonstrated successful long-term survival, ranging from 17 to 104 months post-transplantation.
Impact:
- Living-donor lobar lung transplantation, when combined with meticulous peri-operative care, represents a promising therapeutic strategy for patients with severe infectious lung conditions.
- This approach can lead to favorable long-term survival outcomes, challenging previous limitations in treating such patients.
- The findings underscore the importance of specialized management protocols in optimizing results for lung transplant recipients with infectious diseases.
